Inventiva reports its 2023 full-year results

Revenues at €17.5 million for the full year of 2023 up 43.4% compared to €12.2 million for 2022 Cash and cash equivalents at €26.9 million, short-term deposits at €0.01 million1, and...

Related Keywords

Tianqing ,Zhejiang ,China ,France ,South Korea ,Paris ,France General ,Russia ,Ukraine ,Israel ,United States ,Brussels ,Bruxelles Capitale ,Belgium ,Milan ,Lombardia ,Italy ,Daix ,Bourgogne ,New York ,Cambridge ,Cambridgeshire ,United Kingdom ,Japan ,Chinese ,French ,Gilbert Dupont ,Sino Biopharm ,Julia Cailleteau ,Pascaline Clerc ,Aude Lepreux ,Hepalys Pharma Inc ,Nasdaq ,Corporate Affairs ,Data Monitoring Committee ,Chia Tai Tianqing Pharmaceutical Group Co Ltd ,Brunswick Group ,Market Program ,Patricial Bank ,Exchange Commission ,European Investment Bank On ,Chinese National Medical Products Administration ,University Of Florida ,China National Medical Products Administration ,European Investment Bank ,Patient First Visit ,Long Island City ,Euronext Paris ,Hepalys Pharma ,Suspected Unexpected Serious Adverse Reaction ,Investigational New Drug ,At The Market Program ,National Medical Products Administration ,Breakthrough Therapy Designation ,Kenneth Cusi ,Metabolic Associated Fatty Liver Disease ,Non Alcoholic Fatty Liver Disease ,Phasei Renal Impairment ,Access Event ,European Healthcare Summit ,Annual Conference Liver Connect ,Nasdaq Global Market ,Roquet Montegon ,Private Securities Litigation Reform Act ,New Drug Application ,Universal Registration Document ,Des March ,Annual Report ,Half Year Report ,Year Results ,Markets ,